GeneDx Holdings (WGS) Total Current Liabilities (2020 - 2026)

GeneDx Holdings (WGS) has reported Total Current Liabilities for 7 consecutive years, with $87.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Current Liabilities rose 26.02% year-over-year to $87.6 million; the TTM figure through Mar 2026 stood at $87.6 million (up 26.02% YoY), while the FY2025 annual figure was $108.9 million, up 98.68% from the prior year.
• Total Current Liabilities eased to $87.6 million in Q1 2026 per WGS's latest filing, from $108.9 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $204.6 million in Q2 2022 and bottomed at $50.7 million in Q1 2024.
• Historically, Total Current Liabilities has averaged $95.2 million across 5 years, with a median of $84.4 million in 2023.
• Annual changes were most pronounced in 2022 — Total Current Liabilities jumped 181.77% — and 2023, when it plunged 59.24%.
• GeneDx Holdings' Total Current Liabilities stood at $144.3 million in 2022, then slumped by 59.24% to $58.8 million in 2023, then retreated by 6.8% to $54.8 million in 2024, then soared by 98.68% to $108.9 million in 2025, then retreated by 19.53% to $87.6 million in 2026.
• Business Quant data shows WGS's Total Current Liabilities at $87.6 million in Q1 2026, $108.9 million in Q4 2025, and $87.6 million in Q3 2025.